Form 8-K - Current report:
SEC Accession No. 0001193125-24-248694
Filing Date
2024-10-31
Accepted
2024-10-31 16:16:02
Documents
21
Period of Report
2024-10-28
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d904414d8k.htm   iXBRL 8-K 32213
2 EX-1.1 d904414dex11.htm EX-1.1 234169
3 EX-5.1 d904414dex51.htm EX-5.1 9451
4 EX-99.1 d904414dex991.htm EX-99.1 13586
5 EX-99.2 d904414dex992.htm EX-99.2 14680
6 EX-99.3 d904414dex993.htm EX-99.3 14017
10 GRAPHIC g904414eyepoint.jpg GRAPHIC 5996
11 GRAPHIC g904414g1031080912856.jpg GRAPHIC 2196
12 GRAPHIC g904414g1031085132661.jpg GRAPHIC 4091
  Complete submission text file 0001193125-24-248694.txt   545998

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION SCHEMA eypt-20241028.xsd EX-101.SCH 2861
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE eypt-20241028_lab.xml EX-101.LAB 17237
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE eypt-20241028_pre.xml EX-101.PRE 10820
23 EXTRACTED XBRL INSTANCE DOCUMENT d904414d8k_htm.xml XML 3499
Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Filer) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-51122 | Film No.: 241415442
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)